BCR-ABL
7 drugsBCR-ABL1 Fusion Gene (Philadelphia Chromosome)
Predictive biomarker for patient selection in 3 indications
Understanding BCR-ABL
What it means: BCR-ABL results from a translocation creating the Philadelphia chromosome. The fusion protein has constitutive tyrosine kinase activity.
Why it matters: Tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib, ponatinib) revolutionized CML treatment, achieving long-term remissions.
Testing: Tested via cytogenetics, FISH, or RT-PCR. Quantitative PCR monitors treatment response (molecular response levels).
7
Approved Drugs
3
Indications
6
Companies
BCR-ABL is a precision-medicine biomarker linked to 7 FDA-approved targeted drugs from 6 companies, spanning 3 indications including Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia. Explore the targeted therapies, indications, testing methods, and companies developing BCR-ABL drugs below.
Search BCR-ABL Clinical Trials
Search recruiting trials on ClinicalTrials.gov